###### Strengths and limitations of this study

-   4837 incident cases of cancer (2097 colorectal; 1685 breast; 1055 prostate) have been prospectively followed up, accounting for more than 30 000 patient-years and with only 153 patients (3%) lost to follow-up.

-   The cohort covers a wide spectrum of the Spanish population including 23 hospitals across Spain.

-   A major strength of this study is the amount of information gathered at diagnosis, including sociodemographic, lifestyle, nutrition, familial and personal medical history, reproductive history, use of drugs, sleep, genotyping, clinical and pathological characteristics of the tumour, first-line treatment, side effects, health-related quality of life, and current vital status.

-   Biological samples obtained at recruitment (tumour specimen, blood or saliva, toenail, hair and urine) will allow further investigations on metabolomics, epigenetics and exposure to chemicals such as metals.

-   The multicentre characteristic of the study allows the evaluation of a wide geographical basis and increases the representativeness of the recruited sample, but it also may introduce heterogeneity in the information gathered and in treatment.

Introduction {#s1}
============

Tumour size, node infiltration, metastasis, histology, clinical stage and cancer subtype continue to be the main prognosis factors in patients with cancer in spite of the evolving first-line treatment.[@R1] Little effort, however, has been paid to examine the impact on survival of patient factors, such as lifestyle, genetics or environmental, together with tumour features and treatment.

Large prospective cohort studies on cancer focus on identifying risk factors,[@R6] while clinical cohorts on cancer survival usually aim to analyse survival relationships with tumour properties, first-line treatment or patient characteristics. For instance, Lagendijk *et al*[@R7] analysed data on 129 692 women with breast cancer from the Netherlands Cancer Registry to compare breast conserving therapy and mastectomy in subgroups according to age at diagnosis, stage, systemic therapy, comorbidity, oestrogen/progesterone receptors and Her2 status. Cardwell *et al*[@R8] linked the National Cancer Data Repository to the UK Clinical Practice Research Datalink and mortality data from the Office for National Statistics to investigate if statin use after colorectal cancer diagnosis was associated with better prognosis. Pettersson *et al*[@R9] studied survival after prostate cancer diagnosis in 121 392 Swedish men from the Prostate Cancer data Base Sweden V.3.0, where data were available on age, stage, grade, prostate-specific antigen (PSA) level, model of detection, comorbidity, educational level and primary treatment.[@R9] It is noteworthy that these cohorts were based on cancer registries, where data availability is usually restricted to demographic variables (sometimes including educational level and deprivation), tumour characteristics and few data on comorbidities or healthy habits. A different approach has been the use of the Surveillance, Epidemiology and End Results (SEER) database to retrospectively analyse survivorship with breast cancer,[@R10] colorectal cancer[@R11] or prostate cancer,[@R12] but although the number of participants could be over 100 000, available data are restricted to those recorded for the general purposes of the SEER programme, not specifically for studying survivorship with cancer.

The multicase-control study in Spain (MCC-Spain) includes three prospective cohorts of patients with cancer (colorectal, female breast and prostate) with the aim to investigate long-term survival factors, including cancer characteristics and treatment, but also genetics and other omics, lifestyle (physical activity, nutrition, sleep, toxic habits), occupational exposures (including night shift work), environmental factors such as living area conditions, and medical history, aiming to build integrative prognosis models. This multidisciplinary study will provide a complete evaluation of the biological, clinical, environmental, lifestyle and socioeconomic factors determining survival of patients of the three cancers and of the inter-relationship of these factors. The following are the specific objectives for each cohort: For the colorectal cancer cohort: (1) to study the accomplishment of primary treatment with ESMO (European Society for Medical Oncology) and ASCO (American Society of Clinical Oncology) guidelines and factors associated with it; (2) to study factors associated with survivorship, response to treatment and toxicity due to chemotherapy using genetic, epidemiological and clinical-pathological variables; and (3) to validate those models via comparison with Glasgow Prognostic Score predictions. For the breast cancer cohort: (1) to study whether first-line treatment accomplished the St Gallen International Expert Consensus recommendations; (2) to study factors associated with survivorship, response to treatment and toxicity due to chemotherapy using genetic, epidemiological and clinical-pathological variables; and (3) to validate those models via comparison with the Nottingham Prognostic Index and Adjuvant! For prostate cancer cohort: (1) to analyse the adequacy of initial treatment to the recommendations by the European Association of Urology and the National Institute for Health and Care Excellence; (2) to elaborate models on survivorship, risk of biochemical relapse, quality of life, response to primary treatment and toxicity to chemotherapy/brachytherapy; and (3) to validate survivorship and risk of biochemical relapse models via comparison with Han and Kattan nomograms. In this article, we report the study design, the main description of all three cohorts and the preliminary results on survival.

Cohort description and methods {#s2}
==============================

The MCC-Spain began as a case--control study in 2008, started by the Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), on both genetic and environmental exposures associated with colorectal, female breast, prostate and gastric cancers and chronic lymphocytic leukaemia. Its design has been published elsewhere[@R13]; it recruited 10 183 incident cases and controls between 2008 and 2013 in 12 Spanish provinces (Asturias, Barcelona, Cantabria, Girona, Granada, Gipuzkoa, Huelva, León, Madrid, Murcia, Navarra and Valencia). Using the incident cases originally recruited between 2008 and 2013, and given that in 2016 the MCC-Spain has turned towards the identification of factors associated with cancer prognosis, inception cohorts on colorectal, breast and prostate cancers have been assembled, enrolling the patients for a prospective follow-up carried out in 2017--2018. From here on, we only refer to the recruited cases of colorectal (2140 cases), breast (1738 cases) and prostate (1112 cases) cancers; their distribution by province and hospital appears in [online supplementary table 1](#SP1){ref-type="supplementary-material"} and the flow chart appears in [figure 1](#F1){ref-type="fig"}.

10.1136/bmjopen-2019-031904.supp1

![Flow chart of the participants in the MCC-Spain study. MCC-Spain, multicase-control study in Spain.](bmjopen-2019-031904f01){#F1}

Patient recruitment and public involvement statement {#s2-1}
----------------------------------------------------

Patients recruited were between 20 and 85 years old, had resided in the catchment area for at least 6 months before the recruitment and were able to answer the epidemiological questionnaire, and had incident colorectal, breast or prostate cancer. For the recruitment, study personnel contacted newly diagnosed cancer cases in the 21 collaborating hospitals. Cases were identified as soon as possible after the diagnosis; only histologically confirmed incident cases were included.

Participants are being informed on the project's main results via flyers. There is no other patient involvement.

Information at recruitment and biological samples {#s2-2}
-------------------------------------------------

The information obtained and its timing is summarised in [table 1](#T1){ref-type="table"}.

###### 

Information obtained in the MCC-Spain

  Phase                                                                                                                                                                                                                                                                                                            Measurements                                                                                                                                                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Phase I: recruitment                                                                                                                                                                                                                                                                                             2008--2013                                                                                                                                                                                                                                                 *Contact with newly diagnosed cancer cases.*
  *Trained personnel perform a structured computerised epidemiological questionnaire in a face-to-face interview to obtain the following information:* sociodemographic, personal and familial medical history, use of drugs, reproductive history, physical activity, environmental and occupational exposures.                                                                                                                                                                                                                                                              
  A validated semiquantitative frequency-food questionnaire is self-completed to obtain diet information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Biological samples are obtained:* peripheral blood or saliva, toenail, hair, urine, tumour biopsies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *A genotype of exome is made using the Illumina Infinium HumanExome.*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  *Medical records review by trained personnel to obtain the following:* pathology characteristics, tumour extension, clinical data, first-line treatment, recurrence.                                                                                                                                                                                                                                                                                                                                                                                                        
  For colorectal cancer cases                                                                                                                                                                                                                                                                                      First biopsy, surgical piece dimensions, histological type, carcinoembryonic antigen levels.                                                                                                                                                               
  For breast cancers cases                                                                                                                                                                                                                                                                                         Differentiation's degree, immunohistochemical characteristics.                                                                                                                                                                                             
  For prostate cancer cases                                                                                                                                                                                                                                                                                        Gleason score, D'Amico classification, PSA levels.                                                                                                                                                                                                         
  Phase II: follow-up                                                                                                                                                                                                                                                                                              2017--2018                                                                                                                                                                                                                                                 Medical records review by trained personnel to obtain the following:
  For colorectal cancer cases                                                                                                                                                                                                                                                                                      TNM status at recruitment, first-line treatment, surgical margins, patient status after first-line treatment, appearance of second primary tumour, current patient's vital status.                                                                         
  For breast cancers cases                                                                                                                                                                                                                                                                                         Histological grade at diagnosis, Nottingham index, complete clinical/pathological remission, grade of response to treatment, relapse, second primary tumour, current patient's vital status.                                                               
  For prostate cancer cases                                                                                                                                                                                                                                                                                        PSA concentration, Gleason grade and biopsy characteristics at diagnosis, pathological characteristics of the surgical specimen, first-line treatment, clinical response to first-line treatment, second primary tumour, current patient's vital status.   
  Consult in the IND to realise the vital status of patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Contact by phone to complete specific quality of life questionnaires.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  For colorectal cancer cases                                                                                                                                                                                                                                                                                      SF-12, FACT-Colorectal Symptom Index.                                                                                                                                                                                                                      
  For breast cancer cases                                                                                                                                                                                                                                                                                          SF-12, FACT/NCCN Breast Symptom Index.                                                                                                                                                                                                                     
  For prostate cancer cases                                                                                                                                                                                                                                                                                        SF-12, Charlson Comorbidity Index, FACT-P questionnaire, International Prostate Symptom Score.                                                                                                                                                             

SF-12: 12-Item Short Form Survey; FACT: Functional Assessment of Cancer Therapy (P for prostate, B for breast cancer); FACT/NCCN: Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network.

IND, Índice Nacional de Defunciones; MCC-Spain, multicase-control study in Spain; PSA, prostate-specific antigen; TNM, tumour, node, metastases.

Information about sociodemographic, personal and familial medical history, use of drugs, reproductive history, physical activity, and environmental and occupational exposures was gathered using a standardised questionnaire[@R14] administered by trained personnel in a face-to-face interview. Diet information in the year before diagnosis was obtained using a validated semiquantitative frequency-food questionnaire[@R15] filled by the participants. Both questionnaires can be found at <http://www.mccspain.org>. Biological samples were obtained, including peripheral blood or saliva (from 92% of breast cancer cases, 95% of colorectal cancer cases and 97% of prostate cancer cases), toenail and hair (from 77% and 81% of participants, respectively), urine or tumour biopsies. Regarding peripheral blood, 27 mL was aliquoted in whole blood, plasma, serum and cellular fraction for DNA extraction and stored at −80°C. Saliva was collected from people unable to donate a blood sample.

Genotyping {#s2-3}
----------

From 80% of the participants, a genotype of exome was made using the Illumina Infinium HumanExome. In addition to the about 250 000 exome variants included in the original beadchip, 6000 SNPs previously found in GWAS (Genome-wide Association Study) or localised in metabolic pathways of interest were added on MCC-Spain researchers' request. MCC-Spain has recently obtained funding for carrying out a GWAS with all the participants and to launch an analysis on circulant microRNA in patients with breast cancer.

Initial clinical information {#s2-4}
----------------------------

Trained personnel reviewed the medical records in order to collect information on pathology characteristics, tumour extension, clinical data, first-line treatment and recurrence. For colorectal cancer cases, we documented the first biopsy, tumour location, surgical piece dimensions, histological type according to the International Classification of Diseases for Oncology, Third Edition, tumour, node, metastases (TNM) status, carcinoembryonic antigen levels, and first-line treatment (surgery extension, if done; neoadjuvant, adjuvant or palliative chemotherapy or radiotherapy). For breast cancers, we obtained information on tumour location, differentiation's degree, immunohistochemical characteristics (hormonal receptors, Erb-B2), TNM status and first-line treatment (mastectomy/conservative surgery; neoadjuvant, adjuvant or palliative hormonotherapy, chemotherapy or radiotherapy; target-directed therapy such as trastuzumab). For prostate cancer cases, we gathered information on tumour location, Gleason score, D'Amico classification, TNM status, PSA levels and first-line treatment (none, surgery, hormonotherapy, chemotherapy or radiotherapy, including, when appropriate, the purpose of therapy---neoadjuvant, adjuvant or palliative). TNM status for all three tumours was classified according to TNM sixth edition.

Follow-up information {#s2-5}
---------------------

Follow-up was carried out between 2017 and 2018 by reviewing medical records. For patients with colorectal cancer, we collected data on TNM status at recruitment, first-line treatment, surgical margins, patient status after first-line treatment (free of disease, partial response, progression, relapse or stable disease), appearance of second primary tumour and current patient's vital status. For patients with breast cancer, we gathered information on histological grade at diagnosis, Nottingham index, complete clinical/pathological remission, grade of response to treatment (according to the Miller and Payne system or similar classifications), relapse, second primary tumour and current patient's vital status. For patients with prostate cancer, the information assembled included PSA concentration, Gleason grade and biopsy characteristics at diagnosis, pathological characteristics of the surgical specimen, first-line treatment, clinical response to first-line treatment (stable disease/progression or relapse/unknown), chemical relapses, relapse clinical characteristics (local/metastatic and its location), second primary tumour, and current patient's vital status. Some of these data were obtained in order to double-check the clinical information collected at recruitment.

The National Death Index (Índice Nacional de Defunciones (IND)) was consulted to realise the vital status of patients whose last contact with the hospital had occurred 3 or more months before our revision of his/her medical record. The IND is a nationwide database supported by the Spanish Ministry of Health; it is intended to allow the researchers to establish the vital status of patients under study.[@R16]

Patients alive at follow-up were contacted by phone and asked to complete specific quality of life questionnaires: SF-12[@R17] (12-Items Short Form Survey; colorectal, breast and prostate cancers), FACT-Colorectal Symptom Index[@R18] (Functional Assessment of Cancer Therapy; colorectal cancer), FACT/NCCN (National Comprehensive Cancer Network) Breast Symptom Index[@R19] (breast cancer), and for prostate cancer the Charlson Comorbidity Index,[@R20] the FACT-P questionnaire (Functional Assessment of Cancer Therapy Prostate)[@R21] and the International Prostate Symptom Score.[@R22]

The number of patients with follow-up is 2097 for colorectal, 1685 for breast and 1055 for prostate cancer cohorts. This gives a 91% statistical power for colorectal cancer to detect an HR ≥1.2; an 83% statistical power for breast cancer to detect the same HR; and an 80% statistical power for prostate cancer to detect an HR ≥1.25 (assuming 20% exposed patients and 75%, 90% and 85% survival probability in the non-exposed group, respectively).

Statistical analysis {#s2-6}
--------------------

For preliminary results shown in this paper, data are described using absolute frequencies with percentages and means with SD. Patients who died by any cause before the end of follow-up were classified as events and censored otherwise. Time of follow-up was the difference between date of diagnosis and date of death or date of last contact with the hospital or the researchers. Survival probabilities were obtained using unadjusted Kaplan-Meier estimators. Further analyses should deal with confounding and modifiers using multivariate regression models (eg, Cox or Weibull regression). Initial treatment could be related with both basal factors and survivorship, eventually leading to confounding by indication; it would be controlled using propensity scores.

Ethics {#s2-7}
------

The protocol of MCC-Spain was approved by the ethics committees of the participating institutions.[@R13] At recruitment, all participants were informed about the study objectives and signed an informed consent, which also included the authorisation for following up the patient via medical records or phone calls. Only participants agreeing to being followed up were included in the inception cohorts. Confidentiality of data is secured by removing personal identifiers in the data sets. The database was registered in the Spanish Agency for Data Protection (number 2102672171).

Findings to date {#s3}
================

The MCC-Spain has provided results on the effects of different risk factors. For instance, night shift work increased the risk of more aggressive prostate cancers,[@R23] although this excess risk almost disappeared 20 years after last exposure[@R24]; long-term consumption of calcium channel blockers was associated with higher breast cancer risk in overweight women[@R25]; adherence to the Western dietary patterns increased breast cancer risk in both premenopausal and postmenopausal women[@R26]; first validation in a European population of a risk model for breast cancer developed in American women using both modifiable and non-modifiable risk factors as well as 92 genetic variants[@R27]; use of environmental and genetic factors to elaborate a model to stratify the risk of colorectal cancer[@R28]; and adherence to the World Cancer Research Fund/American Institute for Cancer Research nutrition-based guidelines was associated with lower risk of colorectal and breast cancers, but not of prostate cancer.[@R29] A complete list of published results from MCC-Spain appears in [online supplementary table 2 and supplementary reference list](#SP1){ref-type="supplementary-material"}.

Initial results of the follow-up are shown in this work. [Table 2](#T2){ref-type="table"} displays the main characteristics of the patients; [table 3](#T3){ref-type="table"} details specific information of each tumour; and [table 4](#T4){ref-type="table"} describes first-line treatment.

###### 

Main characteristics of the followed patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                       Category                        Colorectal cancer (n=2097)   Breast cancer\                           Prostate cancer\
                                                                                                              (n=1685)                                 (n=1055)
  ---------------------------------------------- ------------------------------- ---------------------------- ---------------------------------------- ------------------
  Age, mean (±SD)                                                                66.98 (±10.85)               56.5 (±12.6)                             65.86 (±7.38)

  Gender                                         Female                          763 (36.39%)                 1685 (100%)                              --

  Male                                           1334 (63.61%)                   --                           1055 (100%)                              

  Postmenopausal                                 Yes                             --                           1095 (65.0%)                             --

  No                                             --                              589 (35.0%)                  --                                       

  Missing                                        --                              1 (0.1%)                     --                                       

  Histology\                                     Adenocarcinoma: 1882 (89.75%)   Ductal: 1276 (75.7%)         Adenocarcinoma (acinar): 1053 (99.91%)   
  (specific types in each tumour)                                                                                                                      

  Mucinous adenocarcinoma: 125 (5.96%)           Lobular :110 (6.5%)             Others: 2 (0.09%)                                                     

  Signet ring cells adenocarcinoma: 12 (0.57%)   Paget disease: 19 (1.1%)        --                                                                    

  Others: 4 (0.19%)                              Others: 280 (16.6%)             --                                                                    

  Unknown: 74 (3.53%)                            --                              --                                                                    

  Tumour size                                    T0                              98 (4.67%)                   23 (1.4%)                                --

  T1                                             125 (5.96%)                     861 (51.1%)                  227 (21.52%)                             

  T2                                             283 (13.49%)                    424 (25.2%)                  521 (49.38%)                             

  T3                                             1172 (55.89%)                   73 (4.3%)                    98 (9.29%)                               

  T4                                             319 (15.21%)                    39 (2.3%)                    8 (0.76%)                                

  Tis                                            --                              109 (6.5%)                   --                                       

  Missing                                        100 (4.77%)                     156 (9.3%)                   196 (18.58%)                             

  Not evaluable                                  --                              --                           5 (0.47%)                                

  Node infiltration                              N0                              1193 (56.89%)                877 (52.0%)                              271 (25.69%)

  N1                                             515 (24.56%)                    441 (26.2%)                  9 (0.85%)                                

  N2                                             286 (13.64%)                    186 (11.0%)                  --                                       

  N3                                             --                              5 (0.3%)                     --                                       

  Missing                                        103 (4.91%)                     176 (10.4%)                  224 (21.23%)                             

  Not evaluable                                  --                              --                           551 (52.23%)                             

  Metastasis                                     No                              1721 (82.07%)                1376 (81.7%)                             532 (50.43%)

  Yes                                            330 (15.74%)                    41 (2.4%)                    17 (1.61%)                               

  Missing                                        46 (2.19%)                      268 (15.9%)                  215 (20.38%)                             

  Not evaluable                                  --                              --                           291 (27.58%)                             

  Clinical stage                                 0                               77 (3.67%)                   --                                       --

  I                                              338 (16.12%)                    702 (41.7%)                  367 (34.79%)                             

  II                                             673 (32.09%)                    479 (28.4%)                  496 (47.01%)                             

  III                                            569 (27.13%)                    179 (10.6%)                  132 (12.51%)                             

  IV                                             330 (15.74%)                    41 (2.4%)                    17 (1.61%)                               

  Missing                                        110 (5.25%)                     284 (16.9%)                  43 (4.08%)                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Specific information for each cancer

  Specific information for colorectal cancer   Specific information for breast cancer   Specific information for prostate cancer                                                                                                        
  -------------------------------------------- ---------------------------------------- ------------------------------------------ ----------------------- ------------- ----------------------- ---------------- --------------------- --------------
                                                                                                                                   Oestrogen receptor      Positive      1398 (83.0%)            Gleason grade    1 (Gleason score=6)   449 (42.56%)
                                                                                                                                   Negative                244 (14.5%)                                                                  
                                                                                                                                   Missing                 43 (2.6%)     2 (Gleason score=3+4)   299 (28.34%)                           
  Location                                     Right colon                              566 (26.99%)                               Progesterone receptor   Positive      1237 (73.4%)                                                   
  Negative                                     401 (23.8%)                              3 (Gleason score=4+3)                      120 (11.37%)                                                                                         
  Left colon                                   719 (34.29%)                             Missing                                    47 (2.8%)                                                                                            
  Her2                                         Positive                                 294 (17.4%)                                4 (Gleason score=8)     83 (7.87%)                                                                   
  Rectum-sigma                                 791 (37.72%)                             Negative                                   1250 (74.2%)                                                                                         
  Missing                                      141 (8.4%)                               5 (Gleason score=9 or 10)                  65 (6.16%)                                                                                           
  Unknown                                      21 (1%)                                  Intrinsic subtype                          Luminal A               997 (59.2%)                                                                  
                                                                                                                                   Luminal B               331 (19.6%)                                                                  
                                                                                                                                   Her2                    81 (4.8%)     Missing                 39 (3.70%)                             
                                                                                                                                   Basal-like              130 (7.7%)                                                                   
  Differentiation's degree                     I                                        520 (24.8%)                                Luminal ONI             91 (5.4%)     PSA (ng/mL)             11.51 (±16.28)                         
  II                                           1100 (52.46%)                            Non-luminal ONI                            13 (0.8%)                                                                                            
  III                                          247 (11.78%)                             Missing                                    42 (2.5%)               D'Amico       Low risk                325 (30.81%)                           
  Not evaluable                                230 (10.97%)                             Grade                                      I                       329 (19.5%)   Intermediate risk       425 (40.28%)                           
  II                                           520 (30.9%)                                                                                                                                                                              
                                                                                                                                   III                     355 (21.1%)   High risk               284 (26.92%)                           
                                                                                                                                   Missing                 481 (28.5%)   Missing                 21 (1.99%)                             

ONI, otherwise not identified; PSA, prostate-specific antigen.

###### 

First-line treatment

  ---------------------------------------------------------------------------------------------------------------------------------------
  Treatment                             Category       Colorectal cancer                Breast cancer    Prostate cancer
  ------------------------------------- -------------- -------------------------------- ---------------- --------------------------------
  None (active surveillance)                           --                               --               38 (3.6%)

  Surgery                                              Total: 1999 (95.3%)              Conservative:\   Prostatectomy: 639 (61.4%)
                                                                                        1231 (73.1%)     

  Resection: 1800 (85.8%)                                                                                

  Palliative: 127 (6.1%)                Mastectomy:\                                                     
                                        454 (26.9%)                                                      

  No resection: 61 (2.9%)                                                                                

  Others: 11 (0.5%)                                                                                      

  Chemotherapy                          Neoadjuvant    427 (20.4%)                      200 (11.9%)      1 (0.1%)

  Adjuvant                              1024 (48.8%)   664 (39.4%)                      1 (0.1%)         

  Palliative                            67 (3.2%)      25 (1.5%)                        7 (0.7%)         

  Radiotherapy                          Neoadjuvant    401 (19.1%)                      5 (0.3%)         227 (21.5%)

  Adjuvant                              82 (3.9%)      1132 (67.2%)                     36 (3.4%)        

  Palliative                            5 (0.2%)       21 (1.2%)                        2 (0.2%)         

  Endocrine therapy                     Yes            --                               1023 (60.7%)     Adjuvant to surgery: 19 (1.8%)

  Adjuvant to radiotherapy: 99 (9.4%)                                                                    

  Neoadjuvant: 102 (9.7%)                                                                                

  Palliative: 69 (6.5%)                                                                                  

  No                                    --             662 (39.3%)                      689 (65.3%)      

  Others (specify for each tumour)      Endoscopy      Complete resection: 107 (5.1%)   --               --

  Non-complete resection: 62 (3.0%)                                                                      

  Her2-targeted therapy                 --             152 (9.0%)                       --               

  Cryotherapy                           --             --                               21 (2.0%)        

  Transurethral resection               --             --                               4 (0.4%)         
  ---------------------------------------------------------------------------------------------------------------------------------------

Colorectal cancer {#s3-1}
-----------------

Out of 2140 patients with colorectal cancer, 2097 (98%) have been followed. They were 67±10.9 years old on average at recruitment, and 1334 (63.4%) were men. The first case was recruited on 18 March 2007 and the follow-up was closed on 23 August 2018, accounting for 12 813.8 person-years of follow-up. During this period, 819 (39.1%) cases died. Linearised mortality rate was 6.4 per 100 patient-years (95% CI 6.0 to 6.8) ([table 2](#T2){ref-type="table"}).

Most cases (1882, 90%) were adenocarcinoma, and the most frequent location was rectum-sigma (37.7%) and the less frequent right colon (27%). Of the patients, 52% were at clinical stage II or lower, and in 110 patients (5.3%) we could not establish the clinical stage. Of the cancers, 52.5% were moderately differentiated (grade II) and 24.8% well differentiated (grade I) ([table 3](#T3){ref-type="table"}).

Surgery was carried out in 1999 patients with colorectal cancer, and it was for palliative purposes in 127 patients (6.1%). There were 169 patients who were treated via endoscopy, reaching complete resection in 107 of them. There were 1518 (72.4%) patients who received chemotherapy, and most of them (1451) were for adjuvant or neoadjuvant purposes; 488 (23.2%) received radiotherapy (401 neoadjuvant, 82 adjuvant and only 5 palliative) ([table 4](#T4){ref-type="table"}).

The 5-year survival probability estimated via Kaplan-Meier was 71.6% (95% CI 69.6 to 73.5) ([figure 2A](#F2){ref-type="fig"}). Survival was higher in women (74.4%, 95% CI 71.0 to 77.2) than in men (70.0%, 95% CI 67.5 to 72.4) (p\<0.001) ([figure 2B](#F2){ref-type="fig"}). The 5-year survival probability was 85.2% (81.0--88.6) in patients diagnosed with stage I, 84.0% (81.0--86.6) with stage II, 73.4% (69.6--76.9) with stage III and 27.6% (22.9--32.5) with stage IV ([figure 3A](#F3){ref-type="fig"}).

![Kaplan-Meier survival estimates for colorectal cancer (A), colorectal cancer by sex (B), breast cancer (C) and prostate cancer (D).](bmjopen-2019-031904f02){#F2}

![Kaplan-Meier estimates by stage at diagnosis for colorectal cancer (A), breast cancer (B) and prostate cancer (C).](bmjopen-2019-031904f03){#F3}

Breast cancer {#s3-2}
-------------

The maximum span for breast cancer follow-up was 9.5 years (from 13 July 2007 to 22 March 2017). Follow-up was obtained for 1685 out of 1738 patients with breast cancer (97%), adding 10 931 person-years; 206 patients died in the follow-up. The linearised mortality rate was 1.9 per 100 patient-years (95% CI 1.6 to 2.2).

Women with breast cancer were 56.5±12.6 years old on average at recruitment, and 65% were postmenopausal. The most usual type of tumour was ductal (75.7%), followed by lobular (6.5%). Most breast cancers were diagnosed at early stages (71% at stages I or II) and only 41 (2.4%) had metastasised at the time of diagnosis ([table 2](#T2){ref-type="table"}). Of the cancers, 83% were oestrogen receptor-positive, 73.4% progesterone receptor-positive and 17.4% Her2-positive. Regarding intrinsic subtypes, 997 (59.2%) could be classified as luminal A, 331 (19.6%) as luminal B, 81 (4.8%) as Her2 and 130 (7.7%) as basal-like. According to grade of differentiation, moderately differentiated accounted for 30.9% of breast cancers, and well differentiated and bad differentiated accounted for about 20% of cancers each. Grade could not be obtained from medical records in 481 patients (28.5%) ([table 3](#T3){ref-type="table"}).

Conservative surgery was performed in 1231 (73.1%) patients and mastectomy in the remaining 454 (26.9%). Adjuvant or neoadjuvant chemotherapy was administered to 50.3% of patients, while radiotherapy was used in 1158 women (68.7%), endocrine therapy was used in 1023 women (60.7%) and Her2-targeted therapy in 152 patients (9.0%) ([table 4](#T4){ref-type="table"}). Kaplan-Meier 5-year survival with breast cancer was 90.7% (95% CI 89.2 to 92.0) ([figure 2C](#F2){ref-type="fig"}). Women diagnosed with stage I had 97% (95.5--98.1) 5-year survival probability, 91.9% (89.1--94.1) at stage II, 84.1% (77.8--88.7) at stage III and 38.5% (18.6--58.2) at stage IV ([figure 3B](#F3){ref-type="fig"}).

Prostate cancer {#s3-3}
---------------

A total of 1112 men with prostate cancer were recruited and 1055 (94.9%) have been followed up. The first patient was included on 26 January 2008 and the end of follow-up was on 13 July 2018, adding 7169.6 person-years of follow-up. Patients were 65.9 years old on average at recruitment. There were 119 patients who died in the follow-up, making the linearised mortality rate 1.7 per 100 patient-years (95% CI 1.4 to 2.0).

Almost all prostate cancers (99.9%) were adenocarcinoma; 496 (47%) were diagnosed at stage II and 132 (12.5%) at stage III ([table 2](#T2){ref-type="table"}). The level of PSA gives an average of 11.5±16.3 ng/mL. Considering the Gleason score, 42.6% of prostate cancers were well differentiated (Gleason grade=1, ie, Gleason score=6), 28.3% were at Gleason grade 2 (Gleason score=3+4), and only 14.0% were bad differentiated (Gleason grade 4 or 5, ie, Gleason score ≥8). Gleason grade could not be established in 17.4% of patients. D'Amico classification system results in 31.4% of patients with low-risk cancer, 41.1% intermediate-risk and 27.4% high-risk cancer ([table 3](#T3){ref-type="table"}).

Thirty-eight patients with prostate cancer were not treated medically at the beginning, being followed by active surveillance. Prostatectomy was performed in 61.4% cases, radiotherapy in 265 patients (25.1%) and endocrine therapy in 289 patients (27.4%). A small number of patients were treated via transurethral resection, cryotherapy or chemotherapy ([table 4](#T4){ref-type="table"}). The 5-year survival probability by Kaplan-Meier was 93.7% (95% CI 92.0 to 95.1) ([figure 2D](#F2){ref-type="fig"}). Survival probability 5 years after being diagnosed was 94.5% (88.1--97.5) for patients at stage I, 95.6% (93.3--97.2) at stage II, 92.4% (88.5--95.0) at stage III and 70.5% (42.8--88.6) at stage IV ([figure 3C](#F3){ref-type="fig"}).

Strengths and limitations {#s4}
=========================

In this article, we have described how three prospective cohorts on colorectal, breast and prostate cancers have been assembled from patients originally recruited for a case--control study, with 97% patients followed up and accounting for more than 30 000 person-years. This is a main achievement of a network settled within the CIBERESP in 12 Spanish provinces. The study is population-based and included only incident cancers. The amount of detailed information recorded as well as the availability of biological samples at recruitment will allow the identification of genetics, environmental, lifestyle and clinical prognosis factors in three frequent cancers in Spain. In this regard, a remarkable feature of the study is the feasibility of studying cancer risk factors as putative prognosis factors. For example, risk factors already analysed in the case--control phase were diet, circadian cycle disruption, some drugs, endocrine disruptors, artificial light or proximity to green spaces; information regarding these risk factors was recorded at recruitment and is available for a prognosis factor analysis in the follow-up (see [online supplementary material](#SP1){ref-type="supplementary-material"} for a complete reference list of MCC-Spain articles).

Obtaining information on personal history, occupational exposures, diet, physical exercise or other lifestyle components is somewhat subjective as both patients and interviewers could be prone to be influenced by their feelings or beliefs about the hypotheses under study, eventually leading to differential misclassification bias. This could hardly have occurred in this study. First, patients were not aware of the hypotheses. Second, interviewers were familiar with the case--control study, not with the cohort design as it was decided later; therefore, if interviewers or patients have introduced some misclassification, it could probably have been non-differential, eventually leading to bias towards the null,[@R30] which would make more robust the positive findings in this cohort study.

This study also has some weaknesses. First, multicentre studies are double-edged; they are needed in order to include many patients, but they could introduce heterogeneity in both the information gathered and the way patients are treated. In this regard, the analysis of prognosis factors should be adjusted for the hospital of recruitment. Second, 113 participating patients have been lost (43 with colorectal cancer, 53 with breast cancer and 57 with prostate cancer). We have tried to minimise it by searching information in three ways: medical records, phone calls and IND; however, we cannot rule out that some patients without follow-up could have died. It is noteworthy that, due to the small number of patients without follow-up, the maximum bias it could introduce in our survival estimates is 2% for colorectal cancer, 3% for breast cancer and 5% for prostate cancer. Third, we have not obtained information on lifestyle changes after diagnosis, which limits lifestyle analysis to habits before cancer appearance. Fourth, the number of patients included in our cohorts is small compared with those based on cancer registries, limiting the analysis of subgroups.

Summarising, the MCC-Spain study has assembled three cohorts with about 4700 patients with cancer accounting for 30 000 patient-years of follow-up, with only 3% patient withdrawals. The information gathered at recruitment will allow to prospectively investigate clinical, lifestyle, environmental and genetic variables as prognosis factors in colorectal, breast and prostate cancers in Spain.

Samples {#s4-1}
-------

Biological samples were stored at the biobanks supported by Instituto de Salud Carlos III-FEDER: Parc de Salut MAR Biobank (MARBiobanc) (RD09/0076/00036), 'Biobanco La Fe' (RD 09 0076/00021) and FISABIO Biobank (RD09 0076/00058), and also at the Public Health Laboratory from Gipuzkoa, the Basque Biobank, the ICOBIOBANC (sponsored by the Catalan Institute of Oncology), the IUOPA Biobank from the University of Oviedo and the ISCIII Biobank.

Collaborators {#s4-2}
-------------

MCC-Spain already participates in international consortiums such as Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO; <https://www.fredhutch.org/en/labs/phs/projects/cancer-prevention/projects/gecco.html>), Breast Cancer Association Consortium (BCAC; <http://bcac.ccge.medschl.cam.ac.uk/>) and Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL; <http://practical.icr.ac.uk/blog/>), where MCC-Spain would contribute to study interactions among the putative prognosis factors in vast population samples.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

We thank all the subjects who participated in the study and all MCC-Spain collaborators. SNP genotyping services were provided by the Spanish 'Centro Nacional de Genotipado' (CEGEN-ISCIII).

JA-M, AJM and JJJ-M contributed equally.

**Contributors:** JA, AJM, JJJ-M have contributed to the conception and design of the study, considering the same contribution. JAM, AJM, JJJ-M, BP-G, VMa, VMo, PA, EA, SdS, IS, GF-T, JA, DS, RM-G, MDC, NA, GC-V, MP, MK and JL have acquired the data and have been involved in drafting the manuscript. All of them read and approved the final manuscript.

**Funding:** The study was partially funded by the \'Accion Transversal del Cancer\', approved on the Spanish Ministry Council on 11 October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773-Cantabria, PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI17CIII/00034, PI18/00181), by the Fundación Marqués de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (the ICGC CLL-Genome Project is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), by the Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, salud201200057018tra), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejería de Sanidad de la Región de Murcia, by the European Commission (grants FOOD-CT-2006-036224-HIWATE), by the Spanish Association Against Cancer (AECC) Scientific Foundation (GCTRA18022MORE), by the Catalan Government-Agency for Management of University and Research Grants (AGAUR) (grants 2017SGR723 and 2014SGR850), by the Fundación Caja de Ahorros de Asturias, and by the University of Oviedo. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya.

**Competing interests:** None declared.

**Patient consent for publication:** Not required.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data availability statement:** Data are available upon reasonable request.
